Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP951621priorityCriticalpatent/ECSP951621A/en
Publication of ECSP951621ApublicationCriticalpatent/ECSP951621A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Compuestos de fórmula (I) donde R -R , A y B tienen el significado dado en la descripción, son inhibidores de la endotelina y puede ser utilizado para el tratamiento de los trastornos que se asocian con las actividades de la endotelina, como el alto la presión arterial.Compounds of formula (I) where R -R, A and B have the meaning given in the description, are endothelin inhibitors and can be used for the treatment of disorders associated with endothelin activities, such as high blood pressure.
ECSP9516211995-12-191995-12-19
NEW SULFONAMIDES CASE RAN 4019/132
ECSP951621A
(en)
USE OF N-ARYLMETHYLENE ETHYLENEDIAMINE DIACETATE, N-ARYLMETHYLENE IMINODIACETATE OR N,N'-DIARYLMETHYLENE ETHYLENEDIAMINE DIACETATE AGAINST OXIDATIVE STRESS